ID
40953
Beschreibung
The primary focus of this first time in human (FTIH) study was to evaluate the safety and tolerability of GSK1292263 and to estimate GSK1292263 pharmacokinetic (PK) parameters and pharmacodynamic (PD) effects in healthy volunteers. Subject: FTIH, oral, safety, tolerability, pharmacokinetics, glucose, pharmacodynamics, male, female, gastric emptying Indication Studied: Type 2 Diabetes Mellitus Study ID: 111596 Clinical Study ID: 111596 Study Title: A study in healthy volunteers of single doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound alone and when co-administered with sitagliptin Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00783549 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK1292263, Sitagliptin Trade Name: N/A Study Indication: Dyslipidaemias
Stichworte
Versionen (2)
- 25.04.20 25.04.20 -
- 07.06.20 07.06.20 -
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
7. Juni 2020
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
A study in healthy volunteers of single doses of orally administered GSK1292263 to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of the compound alone and when co-administered with sitagliptin
Medical conditions (Liver MEDHX), Liver Event 5-DF
- StudyEvent: ODM
Beschreibung
Drug related liver disease conditions (All drugs including Investigational Product)
Alias
- UMLS CUI-1
- C0023895
- UMLS CUI-2
- C0277579
Beschreibung
Other liver disease conditions
Beschreibung
[hidden] Item is not required
Datentyp
text
Alias
- UMLS CUI [1]
- C2348184
Beschreibung
Specific Condition
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0012634
- UMLS CUI [1,2]
- C2348235
Beschreibung
[hidden] Item is not required
Datentyp
text
Alias
- UMLS CUI [1]
- C2826302
Beschreibung
[hidden]
Datentyp
text
Alias
- UMLS CUI [1]
- C1140263
Beschreibung
[hidden]
Datentyp
text
Alias
- UMLS CUI [1]
- C2347090
Beschreibung
[hidden]
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0805701
- UMLS CUI [1,2]
- C0231175
Beschreibung
Status
Datentyp
integer
Alias
- UMLS CUI [1]
- C0449438
Beschreibung
Other medical conditions
Beschreibung
Drug Allergies
Datentyp
integer
Alias
- UMLS CUI [1]
- C0013182
Beschreibung
Rheumatoid Arthritis
Datentyp
integer
Alias
- UMLS CUI [1]
- C0003873
Beschreibung
Psoriasis
Datentyp
integer
Alias
- UMLS CUI [1]
- C0033860
Beschreibung
Thyroid Disease
Datentyp
integer
Alias
- UMLS CUI [1]
- C0040128
Beschreibung
Inflammatory Bowel Disease
Datentyp
integer
Alias
- UMLS CUI [1]
- C0021390
Beschreibung
Lupus
Datentyp
integer
Alias
- UMLS CUI [1]
- C0409974
Beschreibung
Sjogren's Syndrome
Datentyp
integer
Alias
- UMLS CUI [1]
- C1527336
Beschreibung
Vitiligo
Datentyp
integer
Alias
- UMLS CUI [1]
- C0042900
Ähnliche Modelle
Medical conditions (Liver MEDHX), Liver Event 5-DF
- StudyEvent: ODM
C0262926 (UMLS CUI-2)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
C0014644 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
C3275124 (UMLS CUI [2])
(Comment:en)
(Comment:en)
(Comment:en)
C0277579 (UMLS CUI-2)
C0277579 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
C2348235 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,2])
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)
(Comment:en)